CAPItello-281

Abstract LBA56ESMO 2026GenitourinaryPicked by Dr. Gil Morgan and Dr. Toni Choueiri and Dr. Silke Gillessen and Dr. Neeraj Agarwal and Dr. Tian Zhang and Dr. Tom Powles and Dr. Brian Rini and Dr. Petros Grivas and Dr. Axel Merseburger and Dr. Aurelius Omlin and Dr. Andrea Apolo and Dr. Daniel Heng and Dr. Sumanta Pal and Dr. Enrique Grande and Dr. Hans Hammers and Dr. Natalia Gandur

What it tests: Capivasertib plus abiraterone versus placebo plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer. Updated overall survival results.

Videos

Prostate cancer: EMBARK, CAPItello-281, PETRANHA
Dr. Gil Morgan. Expert pick. ESMO 2025.
Day 3 round-up: the top five trials
Dr. Gil Morgan. Daily round-up. ESMO 2025. Day 3.

The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.

Email address

Your role

Your country

How we use your details

CAPItello-281

Videos

Prostate cancer: EMBARK, CAPItello-281, PETRANHA

Day 3 round-up: the top five trials

The week in oncology, in your inbox